Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.

New research published in JAMA Network Open finds that insulin glargine and other insulin analogs are the most-used forms of insulin in the United States, alongside pen devices as a delivery method.

Early last summer, Walmart announced the launch of a new private brand, cash-pay analog insulin, made by drug manufacturer Novo Nordisk. Sold under Walmart’s private ReliOn label, vials go for $72.88 each and FlexPens for $85.88 each. Walmart calculates that the products will save customers between 58% and 75% of the cash price for branded analog insulin products, which translates to savings of up to $101 per branded vial or $251 per package of branded FlexPens. But, for many who struggle with the day-to-day costs of living with diabetes, these brands may still be tough to afford. Other pharmacies or drug-maker patient assistance programs may offer more support to cash-strapped patients.

GLP-1 receptor agonists may benefit patients who have asthma, suggests new research published in the American Journal of Respiratory and Critical Care Medicine.